Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGENNASDAQ:IMTXNYSE:JATTNASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGENAgenus$3.50+20.3%$2.15$1.38▼$19.69$74.10M1.48583,249 shs3.18 million shsIMTXImmatics$4.56+7.5%$4.48$3.30▼$13.77$554.27M0.87659,713 shs708,574 shsJATTJATT Acquisition$1.21-4.0%$1.28$7.80▼$12.38$20.87MN/A41,322 shs124,568 shsNVAXNovavax$6.34+6.2%$6.86$5.01▼$23.86$1.02B3.217.94 million shs10.24 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGENAgenus0.00%-5.79%+72.35%-9.29%-72.07%IMTXImmatics0.00%-18.93%+2.42%-19.54%-60.85%JATTJATT Acquisition0.00%-17.69%-0.82%-27.11%-74.15%NVAXNovavax0.00%-6.55%+2.22%-26.86%-32.55%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGENAgenus3.7125 of 5 stars3.11.00.04.63.01.70.6IMTXImmatics1.9845 of 5 stars3.61.00.00.03.51.70.0JATTJATT AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ANVAXNovavax3.6689 of 5 stars3.21.00.04.73.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGENAgenus 2.17Hold$8.75150.00% UpsideIMTXImmatics 3.20Buy$16.67265.50% UpsideJATTJATT Acquisition 0.00N/AN/AN/ANVAXNovavax 2.43Hold$17.71179.41% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, AGEN, NVAX, and JATT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/9/2025NVAXNovavaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$9.00 ➝ $7.004/30/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral4/21/2025AGENAgenusB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy4/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/12/2025AGENAgenusRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.00 ➝ $3.003/12/2025AGENAgenusHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral2/28/2025NVAXNovavaxBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.002/27/2025NVAXNovavaxTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGENAgenus$103.46M0.72N/AN/A($7.78) per share-0.45IMTXImmatics$155.84M3.56N/AN/A$2.88 per share1.58JATTJATT AcquisitionN/AN/A$0.04 per share27.08($0.53) per shareN/ANVAXNovavax$682.16M1.49N/AN/A($6.04) per share-1.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGENAgenus-$245.76M-$10.68N/AN/AN/A-145.89%N/A-85.68%5/12/2025 (Estimated)IMTXImmatics-$104.98M$0.14N/AN/AN/A-47.94%-15.90%-9.38%5/13/2025 (Estimated)JATTJATT Acquisition$6.85MN/A0.00∞N/AN/A-49.58%2.84%N/ANVAXNovavax-$545.06M$2.65N/A79.252.85-32.18%N/A-17.05%N/ALatest IMTX, AGEN, NVAX, and JATT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IMTXImmatics-$0.39N/AN/AN/A$14.92 millionN/A5/12/2025Q1 2025AGENAgenus-$1.61-$1.03+$0.58-$1.03$26.38 million$24.07 million5/9/2025Q1 2025NVAXNovavax$0.19$2.93+$2.74$2.93$204.08 million$666.66 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/11/2025Q4 2024AGENAgenus-$2.36-$2.04+$0.32-$2.04$30.09 million$26.84 million2/27/2025Q4 2024NVAXNovavax-$0.75-$0.51+$0.24-$0.51$85.48 million$88.31 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGENAgenusN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AJATTJATT AcquisitionN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGENAgenusN/A0.190.19IMTXImmaticsN/A3.983.98JATTJATT AcquisitionN/A0.150.15NVAXNovavaxN/A0.930.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGENAgenus61.46%IMTXImmatics64.41%JATTJATT Acquisition47.97%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipAGENAgenus4.60%IMTXImmatics3.30%JATTJATT Acquisition20.00%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGENAgenus44021.17 million22.38 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableJATTJATT Acquisition317.25 million13.80 millionNot OptionableNVAXNovavax1,990160.84 million158.58 millionOptionableIMTX, AGEN, NVAX, and JATT HeadlinesRecent News About These CompaniesNovavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings BeatMay 12 at 12:49 PM | seekingalpha.comNotable healthcare headlines for the week: Viatris, Novavax and UnitedHealth in focusMay 11 at 2:10 PM | msn.com67,644 Shares in Novavax, Inc. (NASDAQ:NVAX) Acquired by Raymond James Financial Inc.May 11 at 3:30 AM | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Stoke Therapeutics (STOK), Novavax (NVAX) and McKesson (MCK)May 10 at 6:07 PM | theglobeandmail.comBenzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts MarketsMay 10 at 8:51 AM | benzinga.comCan Novavax’s Q1 Earnings Spark a Comeback for NVAX Stock?May 10 at 12:42 AM | theglobeandmail.comWhy Novavax (NVAX) is a Top Momentum Stock for the Long-TermMay 9 at 10:55 AM | zacks.comNVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View UpMay 9 at 9:55 AM | zacks.comNovavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s ElatedMay 9 at 8:32 AM | msn.comNovavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ...May 9 at 8:32 AM | finance.yahoo.comDeep Track Capital LP Purchases New Stake in Novavax, Inc. (NASDAQ:NVAX)May 9 at 7:51 AM | marketbeat.comDecoding Novavax Inc (NVAX): A Strategic SWOT InsightMay 9 at 1:16 AM | gurufocus.comQ1 2025 Novavax Inc Earnings Call TranscriptMay 9 at 12:16 AM | gurufocus.comNovavax Faces Financial and Regulatory Challenges Amid Uncertain Vaccine ProspectsMay 8, 2025 | tipranks.comNovavax says talks with FDA on COVID vaccine approval ongoing calming investor fearsMay 8, 2025 | msn.comNovavax Hauls in $666M Q1 Windfall, Boosts FY25 OutlookMay 8, 2025 | finance.yahoo.comCOVID Vaccine Maker Novavax Stock Soars 16% - Here's WhyMay 8, 2025 | benzinga.comThursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana?May 8, 2025 | benzinga.comWhy This Shrinking Covid-19 Vaccine Stock Jumped 30%May 8, 2025 | barrons.comNovavax, Inc. (NVAX) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comNovavax Reports First Quarter 2025 Financial Results and Operational HighlightsMay 8, 2025 | investing.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitDoorDash’s Uptrend Is Gaining Momentum in 2025By Thomas Hughes | May 9, 2025View DoorDash’s Uptrend Is Gaining Momentum in 2025IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthBy Jeffrey Neal Johnson | May 8, 2025View IBM's AI Offensive: Assessing IBM's Path to Renewed GrowthIMTX, AGEN, NVAX, and JATT Company DescriptionsAgenus NASDAQ:AGEN$3.50 +0.59 (+20.27%) Closing price 04:00 PM EasternExtended Trading$3.66 +0.16 (+4.43%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.Immatics NASDAQ:IMTX$4.56 +0.32 (+7.55%) Closing price 04:00 PM EasternExtended Trading$4.56 0.00 (0.00%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.JATT Acquisition NYSE:JATT$1.21 -0.05 (-3.97%) As of 05/9/2025JATT Acquisition Corp does not have significant operations. It intends to effect a merger, capital share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company intends to focus on businesses primarily operating in the life sciences sector. JATT Acquisition Corp was incorporated in 2021 and is based in Grand Cayman, the Cayman Islands.Novavax NASDAQ:NVAX$6.34 +0.37 (+6.20%) Closing price 04:00 PM EasternExtended Trading$6.32 -0.01 (-0.24%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
